Close Menu

NEW YORK (GenomeWeb News) – Canadian molecular diagnostics firm Med BioGene said yesterday that it intends to file for an initial public offering "as soon as possible" in the US to support development and commercialization of its gene expression-based assay for early-stage non-small-cell lung cancer.

MBI, based in Vancouver, BC, said that it has retained the services of Rodman & Renshaw as lead underwriter for the IPO, and will float an unspecified number of common shares on the Nasdaq Capital Market.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

ScienceInsider reports that rude and unprofessional paper reviewers are common and can have harmful effects.

The US Senate has confirmed Stephen Hahn as the next commissioner of the Food and Drug Administration, according to the New York Times.

CNBC reports Apple is partnering with Color Genomics to offer its employees free DNA screening for disease.

In Science this week: researchers use CRISPR tool to find gut microbiome molecules involved in immunity, and more.